Indata kontrolleras och kvalitetsskras sedan av SCB fr att skapa aktuell och trovrdig statistik
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
T.KalkumM.et al (2020)
GLP-1 is a synthetic peptide analog of glucagon-like peptide-1 that is widely studied in biochemical and physiological research
Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man
"I remember I asked Kanye, 'Should I do this?' He was like, 'Yes!' That's how he got into music, because he wanted to do music for videogames and wanted to create videogames." But Kardashian was still cautious: "I was like, 'I wonder if people are really going to
